Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (181-190 of 201) with videos related to

Pageof 21
Sort By:
Neuro-Oncology Advances|December 30, 2024
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastomaJoe S Mendez, Adam L Cohen, Midori Eckenstein, et al.
Science Translational Medicine|July 15, 2021
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent modelsLimeng Wu, Sasa Vasilijic, Yao Sun, et al.
Neurology|December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningiomaAndrew D Norden, Keith L Ligon, Samantha N Hammond, et al.
American Journal of Medical Genetics. Part A|December 6, 2011
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2Jaishri O Blakeley, D Gareth Evans, John Adler, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood|February 15, 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trialMatthew J Frigault, Jorg Dietrich, Kathleen Gallagher, et al.
American Journal of Medical Genetics. Part A|May 8, 2016
The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathwayDavid A Stevenson, Lisa Schill, Lisa Schoyer, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Pageof 21

Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
Neuro-Oncology Advances|December 30, 2024
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastomaJoe S Mendez, Adam L Cohen, Midori Eckenstein, et al.
Science Translational Medicine|July 15, 2021
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent modelsLimeng Wu, Sasa Vasilijic, Yao Sun, et al.
Neurology|December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningiomaAndrew D Norden, Keith L Ligon, Samantha N Hammond, et al.
American Journal of Medical Genetics. Part A|December 6, 2011
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2Jaishri O Blakeley, D Gareth Evans, John Adler, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood|February 15, 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trialMatthew J Frigault, Jorg Dietrich, Kathleen Gallagher, et al.
American Journal of Medical Genetics. Part A|May 8, 2016
The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathwayDavid A Stevenson, Lisa Schill, Lisa Schoyer, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Pageof 21